1. Medtech Insight

Exec Chat: Medtronic Diabetes VP Talks Value-Based Health Care

 
• By David Filmore

Medtronic Diabetes exec Suzanne Winter talks with Medtech Insight about her business' approach to value-based health care, including recently inked agreements with insurers such as Aetna and United Healthcare.

Value dial

It's news to virtually no one in the device industry that value-based health care is the foundation on which medtech companies must now approach hospitals, providers, payers and patients with their offerings. New market strategies that emphasize outcomes and cost-savings, and total solutions rather than widgets, are taking on increasing importance.

But what's happening on the ground? One place to look is in the diabetes device sector, where the connection between device-maker and patients is more direct than in surgical device...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.